MedTrace Logo

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

NCT03119883 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-08-09

No results posted yet for this study

Summary

This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clonal plasma cells in MGUS and MM, respectively. It may also allow researchers better determine the transition from MGUS to MM for the development of potential early diagnostic purposes of preventative strategies.

Conditions

  • Monoclonal Gammopathy of Undetermined Significance
  • Plasma Cell Myeloma

Interventions

OTHER

5-Carbon C 13-labeled Glutamine

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Biospecimen Collection

Undergo collection of bone marrow aspirate samples

OTHER

Uniformly-labeled [13C]glucose

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Wilson I Gonsalves, M.D. · Mayo Clinic in Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-02
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03119883 on ClinicalTrials.gov